- Home
- DIBS vs CRDF Comparison
DIBS vs CRDF Comparison
Compare DIBS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | CRDF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.7M | 187.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DIBS | CRDF |
|---|---|---|
| Price | $5.06 | $1.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $10.83 |
| AVG Volume (30 Days) | 211.7K | ★ 1.8M |
| Earning Date | 02-27-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,422,000.00 | $501,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.49 | N/A |
| 52 Week Low | $2.30 | $1.48 |
| 52 Week High | $6.63 | $4.99 |
Technical Indicators
Market Signals| Indicator | DIBS | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 31.47 | 32.46 |
| Support Level | $5.29 | $1.53 |
| Resistance Level | $5.60 | $1.68 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 12.79 | 15.45 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.